Oocyte development in XO foetuses of man and mouse: the possible role of heterologous X-chromosome pairing in germ cell survival

Chromosoma ◽  
1986 ◽  
Vol 94 (2) ◽  
pp. 115-124 ◽  
Author(s):  
R. M. Speed
Keyword(s):  
Germ Cell ◽  
Cell Survival ◽  
X Chromosome ◽  
Chromosome Pairing ◽  
Oocyte Development

The Role of Wnt4/beta-Catenin Signaling in Maintaining Germ Cell Survival in the Fetal Ovary.

2009 ◽  
Vol 81 (Suppl_1) ◽  
pp. 175-175 ◽  
Author(s):  
Chia-Feng Liu ◽  
Keith Parker ◽  
Humphrey Huang-Chang Yao
Keyword(s):  
Germ Cell ◽  
Cell Survival ◽  
Beta Catenin ◽  
Fetal Ovary

X-4 Translocations and Meiotic Drive in Drosophila melanogaster Males: Role of Sex Chromosome Pairing

Genetics ◽  
1987 ◽  
Vol 116 (3) ◽  
pp. 409-413
Author(s):  
Bruce McKee
Keyword(s):  
Drosophila Melanogaster ◽  
Y Chromosome ◽  
X Chromosome ◽  
Chromosome Pairing ◽  
Sex Chromosome ◽  
Meiotic Drive ◽  
Meiotic Pairing ◽  
Size Dependent ◽  
Chromosome Breakpoint

ABSTRACT Males carrying certain X-4 translocations exhibit strongly skewed sperm recovery ratios. The XP4D half of the translocation disjoins regularly from the Y chromosome and the 4PXD half disjoins regularly from the normal 4. Yet the smaller member of each bivalent is recovered in excess of its pairing partner, apparently due to differential gametic lethality. Chromosome recovery probabilities are multiplicative; the viability of each genotype is the product of the recovery probability of its component chromosomes. Meiotic drive can also be caused by deficiency for X heterochromatin. In(1)sc4Lsc8R males show the same size dependent chromosome recoveries and multiplicative recovery probabilities found in T(1;4)BS males. Meiotic drive in In(1)sc4Lsc8R males has been shown to be due to X-Y pairing failure. Although pairing is regular in the T(X;4) males, the striking phenotypic parallels suggest a common explanation. The experiments described below show that the two phenomena are, in fact, one and the same. X-4 translocations are shown to have the same effect on recovery of independently assorting chromosomes as does In(1)sc4Lsc8R. Addition of pairing sites to the 4PXD half of the translocation eliminates drive. A common explanation—failure of the distal euchromatic portion of the X chromosome to participate in X:Y meiotic pairing—is suggested as the cause for drive. The effect of X chromosome breakpoint on X-4 translocation induced meiotic drive is investigated. It is found that translocations with breakpoints distal to 13C on the salivary map do not cause drive while translocations broken proximal to 13C cause drive. The level of drive is related to the position of the breakpoint—the more proximal the breakpoint the greater the drive.

scholarly journals Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3727
Author(s):  
Dafne Jacome Sanz ◽  
Juuli Raivola ◽  
Hanna Karvonen ◽  
Mariliina Arjama ◽  
Harlan Barker ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lipid Metabolism ◽  
Cell Survival ◽  
Drug Testing ◽  
Cancer Metabolism ◽  
Ex Vivo ◽  
Specific Inhibitor ◽  
Low Grade ◽  
Serous Ovarian Cancer

Background: Dysregulated lipid metabolism is emerging as a hallmark in several malignancies, including ovarian cancer (OC). Specifically, metastatic OC is highly dependent on lipid-rich omentum. We aimed to investigate the therapeutic value of targeting lipid metabolism in OC. For this purpose, we studied the role of PCSK9, a cholesterol-regulating enzyme, in OC cell survival and its downstream signaling. We also investigated the cytotoxic efficacy of a small library of metabolic (n = 11) and mTOR (n = 10) inhibitors using OC cell lines (n = 8) and ex vivo patient-derived cell cultures (PDCs, n = 5) to identify clinically suitable drug vulnerabilities. Targeting PCSK9 expression with siRNA or PCSK9 specific inhibitor (PF-06446846) impaired OC cell survival. In addition, overexpression of PCSK9 induced robust AKT phosphorylation along with increased expression of ERK1/2 and MEK1/2, suggesting a pro-survival role of PCSK9 in OC cells. Moreover, our drug testing revealed marked differences in cytotoxic responses to drugs targeting metabolic pathways of high-grade serous ovarian cancer (HGSOC) and low-grade serous ovarian cancer (LGSOC) PDCs. Our results show that targeting PCSK9 expression could impair OC cell survival, which warrants further investigation to address the dependency of this cancer on lipogenesis and omental metastasis. Moreover, the differences in metabolic gene expression and drug responses of OC PDCs indicate the existence of a metabolic heterogeneity within OC subtypes, which should be further explored for therapeutic improvements.

Sign in / Sign up

Export Citation Format

Share Document